Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Price, News & Analysis

Prometheus Biosciences logo

About Prometheus Biosciences Stock (NASDAQ:RXDX)

Advanced Chart

Key Stats

Today's Range
$199.92
$199.92
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
N/A
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RXDX Stock News Headlines

GENIUS Act: Cancel Your Money?
They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—not the government—have been handed control of a new class of programmable money. It’s not called a CBDC, but it acts just like one. Your spending could be tracked, limited, or even frozen—whether you opt in or not. Once this system becomes the default, escape won’t be easy.tc pixel
Prometheus Biosciences (NASDAQ: RXDX)
See More Headlines

RXDX Stock Analysis - Frequently Asked Questions

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.06. Prometheus Biosciences's revenue for the quarter was down 71.8% on a year-over-year basis.

The following companies are subsidiaries of Prometheus Biosciences: Prometheus Laboratories Inc..

Prometheus Biosciences (RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prometheus Biosciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Moderna (MRNA).

Company Calendar

Last Earnings
5/09/2023
Today
9/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RXDX
CIK
1557421
Fax
N/A
Employees
97
Year Founded
1995

Profitability

EPS (Trailing Twelve Months)
($3.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$141.75 million
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%
Return on Equity
-33.50%
Return on Assets
-29.59%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
37.56
Quick Ratio
37.56

Sales & Book Value

Annual Sales
$6.81 million
Price / Sales
1,403.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.12 per share
Price / Book
12.40

Miscellaneous

Outstanding Shares
47,810,000
Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RXDX) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners